Evidence map›Paper›PMID 27490099›Full record

ArticlePloS one2016

Identification of Novel Smoothened Ligands Using Structure-Based Docking.

Celine Lacroix, Inbar Fish, Hayarpi Torosyan, Pranavan Parathaman, John J Irwin, Brian K Shoichet, Stephane Angers

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Celine LacroixDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Inbar FishDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
Hayarpi TorosyanDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
Pranavan ParathamanDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
John J IrwinDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
Stephane AngersDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-7241-9044

Funding

Scalable technologies for illuminating the druggable GPCR-omeU01MH104974 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2014 to 2016
$1.4M
NIMH NIH HHS U01 MH104974
6 · The paper itself

Abstract

The seven transmembrane protein Smoothened is required for Hedgehog signaling during embryonic development and adult tissue homeostasis. Inappropriate activation of the Hedgehog signalling pathway leads to cancers such as basal cell carcinoma and medulloblastoma, and Smoothened inhibitors are now available clinically to treat these diseases. However, resistance to these inhibitors rapidly develops thereby limiting their efficacy. The determination of Smoothened crystal structures enables structure-based discovery of new ligands with new chemotypes that will be critical to combat resistance. In this study, we docked 3.2 million available, lead-like molecules against Smoothened, looking for those with high physical complementarity to its structure; this represents the first such campaign against the class Frizzled G-protein coupled receptor family. Twenty-one high-ranking compounds were selected for experimental testing, and four, representing three different chemotypes, were identified to antagonize Smoothened with IC50 values better than 50 μM. A screen for analogs revealed another six molecules, with IC50 values in the low micromolar range. Importantly, one of the most active of the new antagonists continued to be efficacious at the D473H mutant of Smoothened, which confers clinical resistance to the antagonist vismodegib in cancer treatment.

Indexed as

Molecular Docking SimulationMutation, MissenseNeoplasm ProteinsSmoothened ReceptorAmino Acid SubstitutionAnilidesAnimalsAntineoplastic AgentsHumansMiceMice, KnockoutPyridinesAnilidesAntineoplastic AgentsHhAntag691Neoplasm ProteinsPyridinesSmoothened ReceptorSMO protein, humanSmo protein, mouse

Identifiers

PMID27490099
PMCPMC4973902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.